or Try an Advanced Search...

    Technical Analysis for ENLV - Enlivex Therapeutics Ltd.

    Grade Last Price % Change Price Change
    F 1.38 -2.82% -0.04
    ENLV closed down 2.82 percent on Monday, July 1, 2024, on 37 percent of normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Flat
    Historical ENLV trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Fell Below 50 DMA Bearish -2.82%
    Bollinger Band Squeeze Range Contraction -2.82%
    NR7 Range Contraction -2.82%
    Narrow Range Bar Range Contraction -2.82%
    Inside Day Range Contraction -2.82%
    Gapped Down Weakness -2.82%
    Crossed Above 20 DMA Bullish -8.00%
    Crossed Above 50 DMA Bullish -8.00%
    Older End-of-Day Signals for ENLV ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 9 hours ago
    Down 5% about 9 hours ago
    Down 3% about 9 hours ago
    20 DMA Support about 10 hours ago
    10 DMA Support about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ENLV Chart by TradingView
    Basic chart:

    Profile

    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Immunology Solid Tumors Immune System Immunotherapy Cancer Treatment Tumor Virotherapy Coronavirus Cytokine Inflammatory Conditions

    Is ENLV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
    Jun 20 Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
    Jun 17 Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
    Jun 3 Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
    May 29 Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
    May 28 Enlivex Therapeutics announces up to $15M registered direct offering
    May 28 Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
    May 21 We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate
    Apr 29 Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Apr 29 Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
    See more ENLV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.59
    52 Week Low 1.15
    Average Volume 84,365
    200-Day Moving Average 2.19
    50-Day Moving Average 1.43
    20-Day Moving Average 1.39
    10-Day Moving Average 1.38
    Average True Range 0.14
    RSI (14) 46.24
    ADX 12.48
    +DI 19.90
    -DI 18.49
    Chandelier Exit (Long, 3 ATRs) 1.24
    Chandelier Exit (Short, 3 ATRs) 1.60
    Upper Bollinger Bands 1.50
    Lower Bollinger Band 1.27
    Percent B (%b) 0.47
    BandWidth 16.47
    MACD Line -0.04
    MACD Signal Line -0.06
    MACD Histogram 0.0218
    Fundamentals Value
    Market Cap 25.67 Million
    Num Shares 18.6 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -0.94
    Price-to-Sales 0.00
    Price-to-Book 1.35
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.49
    Resistance 3 (R3) 1.48 1.44 1.47
    Resistance 2 (R2) 1.44 1.41 1.44 1.46
    Resistance 1 (R1) 1.41 1.40 1.39 1.42 1.46
    Pivot Point 1.37 1.37 1.36 1.37 1.37
    Support 1 (S1) 1.34 1.34 1.32 1.35 1.30
    Support 2 (S2) 1.30 1.33 1.30 1.30
    Support 3 (S3) 1.27 1.30 1.29
    Support 4 (S4) 1.28